Albany Molecular Research
Curia Global (formerly Albany Molecular Research Inc.) is a global CDMO with 3,000+ professionals and 20+ facilities across North America, Europe, and India, providing integrated drug discovery, development, and manufacturing services across small molecules, generic APIs, biologics, and sterile drug products to pharmaceutical and biotechnology clients.
- Company typePrivate
- Founded1990
- HeadquartersAlbany, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What Albany Molecular Research does
Albany Molecular Research Inc., founded in 1990 and rebranded as Curia Global in 2021, is a global Contract Development and Manufacturing Organization (CDMO) headquartered in Albany, New York. The company operates more than 20 facilities across North America, Europe, and India with a workforce of over 3,000 professionals, serving pharmaceutical and biotechnology companies that outsource portions of their drug discovery, development, and manufacturing. Its stated mission is guiding clients through the complexities of drug development from discovery through commercial supply, with positioning built on deep scientific expertise, flexible and scalable operations, and global regulatory knowledge.
Curia's service portfolio is organized into four core verticals: Small Molecule, Generic APIs, Biologics, and Sterile Drug Product. The Small Molecule vertical spans assay development and screening, computer-aided drug design (CADD), custom synthesis, medicinal chemistry, DMPK, and chemical process R&D, extending through API manufacturing capabilities that include fermentation, flow chemistry, high-potency compound handling, sterile API manufacturing, industrial chromatography, and controlled substance GMP. The Biologics vertical covers antibody discovery and engineering, mammalian cell line development, mRNA process development and GMP manufacturing, lipid nanoparticle (LNP) formulation, baculovirus expression vector system (BEVS), and GMP drug substance manufacturing. The Sterile Drug Product vertical provides formulation development, process development, and clinical and commercial fill-finish manufacturing. The Generic APIs vertical offers a catalog of active pharmaceutical ingredients plus specialty products and intellectual property services. Supporting the four verticals are comprehensive Analytical Testing Services (batch release, stability, method development and validation, solid-state chemistry) and a Fine Chemicals line that includes proprietary branded products such as Gemagique AMPS Polymers and T3P reagent.
Commercially, Curia operates a direct B2B go-to-market via dedicated business development teams targeting pharma and biotech clients, with no reseller or distributor layer. Revenue is generated through professional-services engagements — primarily custom-quoted, multi-year project contracts — with pricing tied to program complexity, scale, and regulatory scope rather than standardized list rates. The customer base spans large and mid-size pharmaceutical companies seeking to reduce fixed infrastructure costs and improve R&D productivity, alongside biotechnology companies needing specialized capabilities and capital-efficient access to advanced technologies. Over its 30-plus-year history the company has executed a continuous M&A program, acquiring capabilities in biologics (LakePharma, Integrity Bio in 2021), sterile injectables (Oso Biopharmaceuticals in 2014), European API manufacturing (Gadea in 2015, Euticals in 2016), and analytical testing (Whitehouse Laboratories in 2015), transforming a US-centric CRO into a diversified, four-vertical global CDMO.
Albany Molecular Research firmographics
Firmographics- Name
- Albany Molecular Research
- Legal name
- Curia Global, Inc.
- Website
- https://amriglobal.com
- Company type
- Private
- Founded year
- 1990
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Curia Global (formerly Albany Molecular Research Inc.) is a global CDMO with 3,000+ professionals and 20+ facilities across North America, Europe, and India, providing integrated drug discovery, development, and manufacturing services across small molecules, generic APIs, biologics, and sterile drug products to pharmaceutical and biotechnology clients.
- Ownership category
- akta.pro rank
Albany Molecular Research industry classification
Industry- Product category
- Contract Pharmaceutical Development and Manufacturing (CDMO)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- Small-Molecule API & Intermediates CDMO (HLAGABAA), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
Keywords
Where Albany Molecular Research is headquartered
LocationHeadquarters
- HQ city
- Albany
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Albany Molecular Research business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Contract Development and Manufacturing Services: Full-service CDMO providing drug discovery, development, and manufacturing services to pharmaceutical and biotechnology companies. Revenue generated through long-term service contracts and project-based engagements across small molecule, biologics, sterile drug product, and generic API programs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Project-based service contracts |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Albany Molecular Research product offering
Product offeringCore offering
Albany Molecular Research (now Curia Global) is a global Contract Development and Manufacturing Organization (CDMO) providing integrated drug discovery, development, and manufacturing services to pharmaceutical and biotechnology companies. Its offerings span small molecule discovery and API manufacturing, generic APIs, biologics (including mRNA and mammalian cell-based services), and sterile drug product fill-finish, delivered through 20+ facilities across North America, Europe, and India.
Product overview
Curia Global (formerly Albany Molecular Research Inc.) is a global Contract Development and Manufacturing Organization (CDMO) offering integrated pharmaceutical services across four main verticals: Small Molecule, Generic APIs, Biologics, and Sterile Drug Product. The company provides end-to-end capabilities from drug discovery through commercial manufacturing, supported by over 30 years of industry experience and 20+ facilities worldwide. Small Molecule services include discovery (assay development, CADD, custom synthesis, medicinal chemistry, DMPK), development, and API manufacturing. Biologics covers antibody discovery, mRNA services, and GMP mammalian manufacturing. Additional services include analytical testing, fine chemicals, and regulatory support.
Differentiator
Problem solved
Functional benefit
Brands
- Small Molecule: Services covering synthetic chemistry, medicinal chemistry, and process development for small molecule compounds.
- Generic APIs
- Biologics
- Sterile Drug Product
Products and services
- Small Molecule Services
Quantifiable outcome
- Pharmaceutical companies report 65%+ shifting from internal manufacturing toCDMOs by 2025
- +1 more outcomes
Companies that use Albany Molecular Research
Customer profileSegments2 records
Ideal customer profiles3 records
Albany Molecular Research technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Albany Molecular Research partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Identified as Key Player in In-Silico Drug Discovery MarketminorAlbany Molecular Research Inc. (AMRI) is identified as one of the key players in the in-silico drug discovery sector according to market research reports. The company competes alongside Charles River, Certara, Evotec, Schrödinger, and Dassault Systemes (Biovia) among others in this market segment.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Albany Molecular Research competitors and assessment
Company assessmentDirect peers
- Evotec SE: Evotec is a contract research and CDMO organization offering drug discovery, integrated solutions, and manufacturing services. It is named alongside AMRI as a key in-silico drug discovery player and overlaps in early-stage discovery and development services.
- Cambrex: Cambrex is a pure-play CDMO specializing in small molecule API and finished dosage form development and manufacturing. It directly competes with Curia's small molecule and generic API offerings for innovator and generic pharma clients.
- Lonza Group: Lonza is the largest pure-play CDMO globally with deep capabilities in small molecule APIs, biologics, cell and gene therapy, and mammalian manufacturing. It competes with Curia across multiple modalities, particularly in biologics and small molecule API.
- Charles River Laboratories: Charles River provides discovery services, safety assessment, and CDMO capabilities including biologics and cell therapy manufacturing. It is identified as a key in-silico discovery peer alongside AMRI/Curia and competes for early-stage and preclinical outsourcing budgets.
- WuXi AppTec / WuXi Biologics: WuXi AppTec and WuXi Biologics are global CRO/CDMO platforms offering discovery, small molecule API, and biologics manufacturing services. They overlap directly with Curia across small molecule, biologics, and integrated drug discovery offerings.
- Siegfried Holding: Siegfried is a Swiss CDMO specializing in small molecule API manufacturing and finished drug products. It directly competes with Curia's small molecule API, generic API, and sterile drug product verticals.
- Samsung Biologics: Samsung Biologics is a major contract manufacturer of biologics drug substance with very large mammalian cell culture capacity. It is a direct peer to Curia's biologics GMP manufacturing business for mammalian and mRNA clients.
- Catalent: Catalent is a leading global CDMO offering integrated development and manufacturing services across small molecule, biologics, and sterile drug product. It directly competes with Curia in softgel, oral solid, biologics, and sterile fill-finish for pharma and biotech clients.
Broad incumbents
- Eurofins Scientific: Eurofins operates a global network of contract laboratories providing analytical testing, pharma services, and CDMO-adjacent capabilities. It competes with Curia's analytical testing services and shares the broader pharma services buyer base.
- Thermo Fisher Scientific (Patheon): Thermo Fisher operates the Patheon CDMO business alongside a broader life sciences tools and diagnostics portfolio. It competes with Curia in small molecule, sterile fill-finish, and clinical/commercial manufacturing with greater scale and capital.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Albany Molecular Research social profiles
Digital presenceAlbany Molecular Research financial estimates
Financial estimateRevenue estimate
Valuation estimate
Albany Molecular Research leadership team
Management profileNumber of profiles
Profiles1 record
Albany Molecular Research funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Albany Molecular Research M&A and investment
M&A and investmentM&A14 records
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Albany Molecular Research
What does Albany Molecular Research do?
Albany Molecular Research (now Curia Global) is a global Contract Development and Manufacturing Organization (CDMO) providing integrated drug discovery, development, and manufacturing services to pharmaceutical and biotechnology companies. Its offerings span small molecule discovery and API manufacturing, generic APIs, biologics (including mRNA and mammalian cell-based services), and sterile drug product fill-finish, delivered through 20+ facilities across North America, Europe, and India.
Is Albany Molecular Research a public or private company?
Albany Molecular Research is a private company. It is classified as unknown and is currently operating.
When was Albany Molecular Research founded?
Albany Molecular Research was founded in 1990. It employs 1,001 to 5,000 people.
Where is Albany Molecular Research based?
Albany Molecular Research is headquartered in Albany, United States, in the North America region.
How does Albany Molecular Research make money?
One revenue line is on record: contract Development and Manufacturing Services.
Who are Albany Molecular Research's main competitors?
Direct peers on record are Evotec SE, Cambrex, Lonza Group, Charles River Laboratories, WuXi AppTec / WuXi Biologics, Siegfried Holding, Samsung Biologics and Catalent. Broad incumbents are Eurofins Scientific and Thermo Fisher Scientific (Patheon).
Does Albany Molecular Research have an API?
No public API is recorded for Albany Molecular Research.
What industry is Albany Molecular Research in?
Albany Molecular Research's product category is Contract Pharmaceutical Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAA, Small-Molecule API & Intermediates CDMO. Its NAICS code is 325412 and its SIC code is 8731.